肿瘤免疫治疗致甲状腺功能异常的^(99)Tc^(m)O_(4)^(-)SPECT显像分析及文献复习  

Analysis of ^(99)Tc^(m)O_(4)^(-)SPECT imaging and literature review of thyroid function elevation induced by tumor immunotherapy

作　　者：董华[1] 刘东海 李亚男 胡海龙[3] 张遵城[1] Dong Hua;Liu Donghai;Li Yanan;Hu Hailong;Zhang Zuncheng(Department of Nuclear Medicine,the Second Hospital of Tianjin Medical University,Tianjin 300211,China;Department of Medical Imaging,Tianjin Rehabilitation Center,Tianjin 300074,China;Department of Urology,the Second Hospital of Tianjin Medical University,Tianjin 300211,China)

机构地区：[1]天津医科大学第二医院核医学科,300211 [2]天津康复疗养中心医学影像科,300074 [3]天津医科大学第二医院泌尿外科,300211

出　　处：《国际放射医学核医学杂志》2021年第9期607-610,共4页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：近年来,程序性细胞死亡受体1及其配体的抑制性抗体在恶性肿瘤临床治疗试验中的作用已经得到认同。但此类药物会引发一些不良反应,以甲状腺功能障碍为主的免疫相关不良反应越来越被重视。笔者报道了^(99)Tc^(m)O_(4)^(-)SPECT显像在2例肿瘤免疫治疗后甲状腺功能异常患者中的应用。Recently,the role of inhibitory antibodies to programmed cell death 1 receptor and programmed cell death ligand 1 in clinical treatment trials of malignant tumors has been recognized.But such drugs can cause some adverse reactions,and the immune-related adverse events,especially thyroid dysfunction,are paid more and more attention.Application of ^(99)Tc^(m)O_(4)^(-)SPECT imaging in 2 patients with elevated thyroid function after tumor immunotherapy was reported.

关 键 词：免疫疗法 单光子发射计算机体层摄影术 99m锝高锝酸盐 程序性细胞死亡受体1 程序性细胞死亡配体1 甲状腺功能亢进症 甲状腺功能减退症 

分 类 号：R730.51[医药卫生—肿瘤]